Triplet OK'd as First-Line Therapy in Melanoma

(MedPage Today) -- The FDA on Thursday approved the PD-L1-directed immune checkpoint inhibitor atezolizumab (Tecentriq) for advanced melanoma patients with a BRAF V600 mutation, to be used in combination with targeted agents, Genentech announced...